Citi analyst Patrick Donnelly added Danaher (DHR) to the firm’s Focus List while keeping a Buy rating on the shares with a $165 price target The firm sees an attractive opportunity to step into the name, saying the bioprocessing recovery continues to materialize.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher Positioned for Growth: Strong mAb Demand and Strategic Acquisitions Drive Buy Rating
- Danaher price target lowered to $250 from $275 at Guggenheim
- Investors should buy Codexis following contract news, says Craig-Hallum
- FedEx downgraded, Adobe upgraded: Wall Street’s top analyst calls
- Morning Movers: FedEx, Nike headline dip in corporate outlooks